Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Brian Abrahams

Biotech Stocks Take Another Beating As 'Chaos' Reigns At FDA With Reports Of Mass Firings

Biotech stocks skidded again Tuesday as "chaos" reigned at the FDA with reports of mass firings, including the departure of a key official.

Investors Business Daily

Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower

Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed.

Investors Business Daily

Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'

Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

The Senate voted Thursday to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

Investors Business Daily

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.

Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

Investors Business Daily

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

Investors Business Daily

Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock

The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late Friday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease

Prothena stock catapulted Thursday after the company's Roche-partnered Parkinson's treatment showed promise in a midstage study.

Investors Business Daily

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts

In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX), offering a diverse range of perspectives from bullish to bearish.

Benzinga

Assessing Biogen: Insights From 19 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months.

Benzinga

Analyst Expectations For Sarepta Therapeutics's Future

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Benzinga

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise

Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise.

Investors Business Daily

Vertex Flashes A Surprise Buy Point As Non-Opioid Pain Drug Looms

Vertex beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday.

Investors Business Daily

Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.

Biogen stock dipped Wednesday despite an unexpected boost from its new Alzheimer's drug, Leqembi, and an earnings guidance hike.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention

Gilead stock popped Thursday after the biotech giant said its twice-yearly shot prevented 99.9% of HIV infections in a study.

Investors Business Daily

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes

Dyne Therapeutics stock crashed Tuesday after several key executives departed on the heels of what the company calls "unprecedented" in DMD.

Investors Business Daily

Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats

Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.

Investors Business Daily

Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug

Biogen stock tumbled Friday after European regulators rejected its Eisai-partnered Alzheimer's treatment, citing steep side effects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug

Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.

Investors Business Daily

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.

Investors Business Daily

Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club

Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.

Investors Business Daily

Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower

Eli Lilly stock seesawed Tuesday after a Food and Drug Administration panel endorsed its Alzheimer's treatment, donanemab.

Investors Business Daily

Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug

Neumora said Monday the FDA put its schizophrenia drug on hold after rabbits experienced convulsions, and the biotech stock plunged.

Investors Business Daily

Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?

Regeneron stock toppled Thursday after the DOJ filed a lawsuit saying the drugmaker fraudulently inflated the prices of its drug, Eylea.

Investors Business Daily

The $1 Billion Opportunity Driving IBD Stock Of The Day Neurocrine Higher

Neurocrine s Monday's IBD Stock Of The Day. Milestones are stacking up in 2024 and Neurocrine stock just topped its 50-day line.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals

178 stories

RBC Capital

177 stories

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.